Ocular Therapeutix (OCUL) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Cantor Fitzgerald Reiterates Overweight on Ocular Therapeutix (OCUL) Following 1Q
May 9, 2018 8:01 AM EDTCantor Fitzgerald reiterated an Overweight rating and $22.00 price target on Ocular Therapeutix (NASDAQ: OCUL) following the company's 1Q earnings report. Management reported a 1Q18 year-end cash and equivalents balance of $63 million, which analyst Elemer Piros believes provides a cash runway beyond a... More
